Collectively, these findings uncover a previously unrecognised MAPK/ERK‐UBE2T‐FA axis in glioma and highlight BA as a potential adjuvant to overcome cisplatin resistance through transcriptional repression of UBE2T. This evidence concerns the gene UBE2T and central nervous system cancer.